Education
About Us
Working with TipRanks
Follow Us
HLS Therapeutics Inc (TSE:HLS)
TSX:HLS
Total Valuation
HLS Therapeutics Inc has a market cap or net worth of C$137.60M. The enterprise value is C$143.17M.
Market CapC$137.60M
Enterprise ValueC$143.17M
Share Statistics
HLS Therapeutics Inc has 31,273,682 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding31,273,682
Owned by Insiders<0.01%
Owned by Institutions1.60%
Financial Efficiency
HLS Therapeutics Inc’s return on equity (ROE) is -0.21 and return on invested capital (ROIC) is -3.48%.
Return on Equity (ROE)-0.21
Return on Assets (ROA)-0.09
Return on Invested Capital (ROIC)-3.48%
Return on Capital Employed (ROCE)-0.04
Revenue Per Employee613.82K
Profits Per Employee-137.47K
Employee Count92
Asset Turnover0.41
Inventory Turnover4.00
Valuation Ratios
The current PE Ratio of HLS Therapeutics Inc is ―. HLS Therapeutics Inc’s PEG ratio is 0.25.
PE Ratio―
PS Ratio1.96
PB Ratio1.80
Price to Fair Value1.80
Price to FCF7.00
Price to Operating Cash Flow6.16
PEG Ratio0.25
Income Statement
In the last 12 months, HLS Therapeutics Inc had revenue of 56.47M and earned -12.65M in profits. Earnings per share was -0.40.
Revenue56.47M
Gross Profit24.01M
Operating Income―
Pretax Income-13.10M
Net Income-12.65M
EBITDA18.02M
Earnings Per Share (EPS)-0.40
Cash Flow
In the last 12 months, operating cash flow was 17.07M and capital expenditures -1.42M, giving a free cash flow of 15.65M billion.
Operating Cash Flow17.07M
Free Cash Flow15.65M
Free Cash Flow per Share0.50
Dividends & Yields
HLS Therapeutics Inc pays an annual dividend of C$0.05, resulting in a dividend yield of ―
Dividend Per ShareC$0.05
Dividend Yield―
Payout Ratio―
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.81
52-Week Price Change6.54%
50-Day Moving Average4.54
200-Day Moving Average5.00
Relative Strength Index (RSI)43.34
Average Volume (3m)19.90K
Important Dates
HLS Therapeutics Inc upcoming earnings date is May 7, 2026, Before Open (Confirmed).
Last Earnings DateMar 12, 2026
Next Earnings DateMay 7, 2026
Ex-Dividend Date―
Financial Position
HLS Therapeutics Inc as a current ratio of 1.11, with Debt / Equity ratio of 80.79%
Current Ratio1.11
Quick Ratio0.80
Debt to Market Cap0.44
Net Debt to EBITDA2.11
Interest Coverage Ratio-0.58
Taxes
In the past 12 months, HLS Therapeutics Inc has paid -452.79K in taxes.
Income Tax-452.79K
Effective Tax Rate0.03
Enterprise Valuation
HLS Therapeutics Inc EV to EBITDA ratio is 8.25, with an EV/FCF ratio of 9.41.
EV to Sales2.63
EV to EBITDA8.25
EV to Free Cash Flow9.41
EV to Operating Cash Flow9.28
Balance Sheet
HLS Therapeutics Inc has C$11.70M in cash and marketable securities with C$49.73M in debt, giving a net cash position of -C$38.03M billion.
Cash & Marketable SecuritiesC$11.70M
Total DebtC$49.73M
Net Cash-C$38.03M
Net Cash Per Share-C$1.22
Tangible Book Value Per Share-C$1.39
Margins
Gross margin is 71.88%, with operating margin of -7.40%, and net profit margin of -22.40%.
Gross Margin71.88%
Operating Margin-7.40%
Pretax Margin-23.20%
Net Profit Margin-22.40%
EBITDA Margin31.91%
EBIT Margin-7.40%
Analyst Forecast
The average price target for HLS Therapeutics Inc is C$8.23, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price TargetC$8.23
Price Target Upside87.05% Upside
Analyst ConsensusModerate Buy
Analyst Count2
Revenue Growth Forecast0.73%
EPS Growth Forecast33.51%